Serenoa repens (Permixon®). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia

Drugs and Aging

Volumn 9, Issue 5, 1996, Pages 379-395

  Plosker, Greg L ^a   Brogden, Rex N ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN RECEPTOR; ANDROSTANOLONE; DOXAZOSIN; FINASTERIDE; OXIDOREDUCTASE; TERAZOSIN;

ABDOMINAL PAIN; BACKACHE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MIXTURE; DYSURIA; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; IMPOTENCE; MALE; NAUSEA; NOCTURIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RECEPTOR BINDING; REVIEW; SABAL; SEXUAL DYSFUNCTION; URINE FLOW RATE; URINE RETENTION;

SERENOA REPENS;

EID: 0029859371     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609050-00008     Document Type: Review

References (86)

1. 14C] beta-sitosterol. Eur J Drug Metab Pharmacokinet. In press
2. Fitzpatrick JM, Lynch TH. Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia. Urol Clin North Am 1995; 22 (2): 407-12
3. Neuzil E, Cousse H. The Saw palmetto Serenoa repens: botanical and chemical aspects. Bull Soc Pharm Bordeaux 1993; 132: 121-41
4. Raynaud J-P. Permixon®: an overview of its pharmacological activities as regards medical treatment of benign prostatic hypertrophy (BPH). In: Dimopoulos CA. Di Silverio F, editors. BPH: From molecular biology to patient relief. Proceedings of the satellite symposium held during the 4th Mediterranean Congress of Urology: 1995 Sep 6-10; Rhodes. Bologna: Monduzzi Editore, 1996: 57-69
5. Isaacs JT, Brendler CB, Walsh PC. Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate. J Clin Endocrinol Metab 1983; 56: 139-46
6. Imperato-McGinley G, Gautier T, Zirinsky K, et al. Prostate visualisation studies in male homozygous and heterozygous for 5α-reductase deficiency. J Clin Endocrinol Metab 1992; 75: 1022-6
7. Bruchovsky N. Comparison of the metabolites found in rat prostate following the in vivo administration of 7 natural androgens. Endocrinology 1971; 89: 1212-8
8. Sitteree PK, Wilson JD. Dihydrotestosterone of prostatic hypertrophy. 1. The formation and content of dihydrotestosterone in the hypertrophic state of man. J Clin Invest 1970; 49: 1737-45
9. Walsh PC, Hutchins GM, Ewing LL. Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal. J Clin Invest 1983; 72: 1772-7
10. Délos S, Iehlé C, Martin PM, et al. Inhibition of the activity of 'basic' 5 α-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 1994 Mar; 48: 347-52
11. Iehlé C, Délos S, Guirou O, et al. Human prostatic steroid 5α-reductase isoforms - a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995; 54: 273-9
12. Strauch G, Perles P, Vergult G, et al. Comparison of finasteride (Proscar®) and Serenoa repens (Permixon®) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994; 26: 247-52
13. Briley M, Carilla E, Roger A, et al. A new treatment of prostatic hyperplasia. Permixon® has antiandrogen effects at two complementary levels. New Trends Androlog Sci 1985; 1 (1): 24-6
14. Carilla E, Briley M, Fauran F, et al. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem 1984 Jan; 20: 521-3
15. Carilla E, Roger A, Briley M, et al. The lipido-sterolic extract of Serenoa repens B: new treatment of prostatic hyperplasia. with anti-androgen effects at two complementary levels. Excerpta Medica 1986: 216-23
16. Sultan C, Terraza A, Devillier C, et al. Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa Repens B" in human foreskin fibroblasts. J Steroid Biochem 1984; 20 (1): 515-9
17. Sultan C, Terraza A, Carilla E, et al. Anti-androgenic effects of Permixon: in vitro studies. New trends in BPH etiopathogenesis. Proceedings of the International Workshop in Urology; 1987 Jul 22-25; Cannes, Rome; Acta Medica, 1988: 239-246.
18. Farnsworth WE, Permixon®: antagonist of prolactin (PRL) action on the prostate [abstract no. 749]. 73rd Annual Meeting of the Endocrine Society, Washington, USA.
19. Vacher P, Prevarskaya N, Skryma R, et al. The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal transduction. J Biomed Sci 1995; 2: 357-65
20. 4) from human polymorphonuclear neutrophils. Prostaglandins Leukotrienes and Medicine. In press
21. 2 activity and on arachidonic acid metabolism in cultured prostatic cells. New trends in BPH etiopathogenesis 1987: 293-6
22. Crastes de Paulet A, Dumon M, Le Doucen C, et al. Anti-inflammatory and antiagregant activities of a lipido-sterolic extract from Serenoa repens on human neutrophiles and on human platelets models. Pierre Fabre Médicaments. (Data on file)
23. Paubert Braquet M, Janssen DH, Servent N, et al. Permixon® [lipido sterolic extract of Serenoa repens (LSESr)] inhibits b-FGF- and EGF-induced proliferation of human prostate organotypic cell lines [abstract]. Pharmacol Res 1995; 31 Suppl.: 69
24. Di Silverio F, Sciarr A, D'Eramo G, et al. Response of tissue androgen and epidermal growth factor concentrations to the long-term administration of Serenoa repens (Permixon®), finasteride and flutamide to BPH patients. Eur Urol 1996; 30 Suppl. 2: 96
25. Tarayre JP, Delhon A, Lauressergues H, et al. Anti-edematous action of a hexane extract of the stone fruit of Serenoa repens Bartr [in French]. Ann Pharm Fr 1983; 41: 559-70
26. Di Silverio F, D'Eramo G, Lubrano C, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy. Eur Urol 1992; 21: 309-14
27. Rhodes L, Primka RL, Berman C, et al. Comparison of finasteride (Proscar®), a 5-α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-α reductase inhibition. Prostate 1993; 22 (1): 43-51
28. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc Natl Acad Sci USA 1990; 87: 3640-4
29. Jenkins EP, Andersson S, Imperato-McGinley G, et al. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest 1992; 89: 293-300
30. Andersson S, Berman DM, Jenkins EP, et al. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 1991; 354: 159-61
31. Bonnet P, Reiter E, Bruyninx M, et al. Benign prostatic hyperplasia in normal prostate aging: differences in types I and II 5 alpha reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels but not in insulin like growth factor mRNA levels. J Clin Endocrinol Metab 1993; 77: 1203-8
32. Hirsch KS, Jones CD, Audia JE, et al. LY191704: a selective, nonsteroidal inhibitor of human steroid 5α-reductase type 1. Proc Natl Acad Sci USA 1993; 90: 5277-81
33. Iehlé C, Raynaud J-P, Martin P-M, et al. Steroid 5α-reductase type 1 is expressed in the human pathological prostate [abstract]. J Urol 1996 May; 155 (5) Suppl.: 808
34. Rennie PS, Bruchovsky N, McLaughlan MG, et al. Kinetic analysis of 5α-reductase isoenzymes in benign prostatic hyperplasia (BPH). J Steroid Biochem 1983; 19: 169-73
35. Ross M, Chapman K, Habib FK. The expression of type 1 and type 2 5-alpha reductase mRNA in BPH and prostate cancer and in short term primary cultures of prostate epithelial and stromal cells [abstract]. British Prostate Group: Future Perspectives in Prostatic Disease; 1996; 19-20 Mar: The University of York, UK, p22.
36. Levine AC, Wang J-P, Ren M, et al. Immunohistochemical localization of steroid 5α-reductase 2 in the human male fetal reproductive tract and adult prostate. J Clin Endocrinol Metab 1996; 81 (1): 384-9
37. Habib F, Grant E, BPH and current biochemical trends. In press
38. Silver I, Wiley EL, Davis DL, et al. Expression and regulation of steroid 5α-reductase 2 in prostate disease. J Urol 1994; 152: 433-7
39. Silver I, Wiley EL, Thigpen AE, et al. Cell type specific expression of 5α-reductase 2. J Urol 1994; 152: 438-42
40. Thigpen AE, Silver RI, Guiteyardo JM, et al. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest 1993; 92: 903-10
41. Tsai SY, Tsai M-J, O'Malley BW. The steroid receptor superfamily: transactivators of gene expression. In: Parker MG, editor. Nuclear hormone receptors. London: Academic Press, 1991: 103-24
42. Ravenna L, Di Silverio F, Russo M, et al. Effects of the lipidosterolic extract of Serenoa repens (Permixon®) on human prostatic cell lines. Prostate. In press
43. Robinette CL. Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate 1988; 12: 271-86
44. Theyer G, Kramer G, Assmann I, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66: 96-107
45. Paubert-Braquet M, Richardson FO, Servent-Saez N, et al. Effect of Serenoa repens extract (Permixon®) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol Res. In press
46. Stenger A, Tarayre J-P, Carilla E, et al. Pharmacologic and biochemical study of the hexane extract of Serenoa repens B (PA 109). La Gazette Médicale de France 1982; 89 (17): 2041-8
47. De Bernardi di Valserra M, Tripodi AS, Contos S, et al. Serenoa repens capsules: a bioequivalence study. Acta Toxicol Ther 1994; 15 (1): 21-39
48. Oesterling JE. Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N Engl J Med 1995; 332 (2): 99-109
49. Geller J, Kirschenbaum A, Lepor H, et al. Therapeutic controversies: clinical treatment of benign prostatic hyperplasia. J Clin Endocrinol Metab 1995; 80 (3): 745-8
50. 1-Blockers vs 5α-reductase inhibitors in benign prostatic hyperplasia: a comparative review. Drugs Aging 1995; 6 (5): 388-96
51. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
52. Clinton JJ. Benign prostatic hyperplasia (BPH) - diagnosis and treatment. JAMA 1994 Apr 20; 271: 1151
53. Lepor H, Nitti VW. Treatment of benign prostatic hyperplasia. Reply [letter]. Lancet 1996 May 4; 347: 1270
54. Authie D, Cauquil J. A multicenter study of the efficacy of Permixon in daily practice [in French]. C R Ther Pharmacol Clin 1987; 5 (56): 3-13
55. Ebbinghaus KD. Efficacy of Permixon® in the treatment of benign prostatic hyperplasia [in German]. Journal Für Urologie und Urogynäkologie 1995; 2: 17-21
56. Barreto HP, de Vivero C, Castro LEC, et al. Advances in the medical management of benign prostatic hyperplasia [in Spanish]. Tribuna Medica 1995; 91 (4): 197-205
57. Hanus M, Matouskova M. Alternative treatment of benign prostatic hypertrophy by Permixon (Capistan) [in Czech]. Rozhl Chir 1993 Feb; 72: 75-9
58. Mancuso G, Guillot F, Migaleddu V, et al. Serenoa repens in treatment of benign prostate hypertrophy [in Italian]. Urologia 1986; 53 (5): 709-14
59. Martorana G, Giberti C, Pizzorno R, et al. Treatment of prostate adenoma with Serenoa repens extract [in Italian]. Urologia 1986; 53 (3): 366-9
60. Olle-Carreras J. Our experience with a hexane extract of Serenoa repens in the treatment of benign prostatic hypertrophy [in Spanish]. Arch Esp Urol 1987 Jun; 40: 310-3
61. Orfei S, Grumelli B, Galetti G. Clinical and flowmetric study of Permixon in aged patients [in Italian]. Urologia 1988; 55 (4): 373-81
62. Paoletti PP, Francalanci R, Tenti S, et al. Medical treatment of prostate hypertrophy: trial with the therapeutic use of Serenoa repens [Italian]. Urologia 1986; 53 (2): 182-7
63. Pescatore D, Calvi P, Michelotti P. Urodynamic evaluation of management of prostatic adenoma with Serenoa repens extracl [in Italian]. Urologia 1986; 53 (6): 894-7
64. Pisani E. National experience on therapeutic use of Serenoa repens. New Trends Androlog Sci 1985; 1 (1): 110-2
65. Tenaglia R, D'Eramo G, Bertolizzi L, et al. Mechanism of action of Serenoa repens: considerations and conclusions. New Trends Androlog Sci 1985; 1 (1): 132-4
66. Vespasiani G, Cesaroni M, Parziani S, et al. Treatment of benign prostatic hypertrophy with Serenoa repens [in Italian]. Urologia 1987; 54 (2): 145-9
67. Dathe G, Schmid H. Phytotherapy of benign prostate hyperplasia with Serenoa repens extract (Permixon registered ) [in German]. Urologe Ausg B 1991; 31 (5): 220-3
68. Boccafoschi C, Annoscia S. Comparison of Serenoa repens extract and placebo in controlled clinical trial in patients with prostatic adenomatosis [in Italian]. Urologia 1983; 50 (6): 1-14
69. Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Screnoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984 Sep; 18: 461-2
70. Cukier, Ducassou, Le Guillou, et al. Serenoa repens extract vs. placebo. CR Ther Pharmacol Clin 1985; 4 (25): 15-21
71. Descotes JL, Rambeaud JJ, Deschaseaux P, et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995 May; 9: 291-7
72. Emili E, Lo Cigno M, Petrone U. Clinical results on a new drug in the treatment of benign prostatic hyperplasia (Permixon) [in Italian]. Urologia 1983; 50 (5): 1042-9
73. Reece Smith H, Memon A, Smart CJ, et al. The value of Permixon in benign prostatic hypertrophy, Br J Urol 1986 Feb; 58: 36-40
74. Tasca A, Barulli M, Cavazzana A, et al. Treatment of obstruction in prostatic adenoma using an extract of Serenoa repens. Double-blind clinical test v. placebo [in Italian]. Minerva Urol Nefrol 1985; 37 (1): 87-91
75. Carraro J-C, Raynaud J-P, Koch G, et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate. In press
76. Grasso M, Montesano A, Buonaguidi A, et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995 Jan-Feb; 48: 97-103
77. Adriazola Semino M, Lozano Ortega JL, Garcia Coho E, et al. Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and Serenoa repens [in Spanish]. Arch Esp Urol 1992 Apr; 45: 211-3
78. Mandressi S, Tarallo U, Maggioni A. et al. Medical treatment of benign prostatic hyperplasia: efficacy of the extract of Serenoa repens (Permixon®) compared to that of the extract of Pygeum africanum and a placebo [in Italian]. Urologia 1983; 50 (4): 752-8
79. Pannunzio E, D'Ascenzo R, Giardinetti F, et al. Serenoa repens vs. gestonorone caproate in treatment of benign prostatic hypertrophy [in Italian]. Urologia 1986; 53 (5): 696-705
80. Peters DH, Sorkin EM, Finasteride: a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993; 46 (1): 177-208
81. Anon. Benign prostatic hyperplasia: diagnosis and treatment: guideline overview. J Natl Med Assoc 1994 Jul; 86: 489-549
82. McCarthy M. BPH guidelines. Lancet 1994 Feb 19; 343: 473
83. Eri LM, Tveter KJ. α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995; 154: 923-34
84. Madsen FA, Bruskewitz RC. Benign prostatic hyperplasia: pathophysiology and pharmacological treatment. Curr Opin Nephrol Hypertension 1995; 4: 455-9
85. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335 (8): 533-9
86. Walsh PC. Treatment of benign prostatic hyperplasia [editorial]. N Engl J Med 1996; 335 (8): 586-7